Zymeworks

Zymeworks Revenue

The The revenue of Zymeworks (ZYME) as of Oct 31, 2026 is 105.97 M USD. In the previous year, The revenue was 76.30 M USD — a change of 38.87% (higher).

Revenue

105.97 MUSD

YoY

38.87%

Last updated:

In 2025, Zymeworks's sales reached 105.97 M USD, a 38.87% difference from the 76.30 M USD sales recorded in the previous year.

Over the last 11 years Zymeworks grew revenue by 45.8% annually, reaching 105.97 M USD.

The Zymeworks Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2023
76.01 M USD
Jan 1, 2024
76.30 M USD
Jan 1, 2025
105.97 M USD
Jan 1, 2026 (e)
298.09 M USD
Jan 1, 2027 (e)
349.18 M USD
Jan 1, 2028 (e)
254.96 M USD
Jan 1, 2029 (e)
411.19 M USD
Jan 1, 2030 (e)
503.96 M USD
The Zymeworks Revenue history
YEARRevenueYoY
est503.96 MUSD+22.56%
est411.19 MUSD+61.28%
est254.96 MUSD-26.98%
est349.18 MUSD+17.14%
est298.09 MUSD+181.31%
105.97 MUSD+38.87%
76.30 MUSD+0.38%
76.01 MUSD-81.57%
412.48 MUSD+1,446.03%
26.68 MUSD-31.50%
38.95 MUSD+31.84%
29.54 MUSD-44.28%
53.02 MUSD+2.43%
51.76 MUSD+370.18%
11.01 MUSD+13.96%
9.66 MUSD+478.44%
1.67 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zymeworks Revenue

Zymeworks Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
76.01 M USD
-138.05 M USD
-118.67 M USD
Jan 1, 2024
76.30 M USD
-137.11 M USD
-122.70 M USD
Jan 1, 2025
105.97 M USD
-92.54 M USD
-81.13 M USD
Jan 1, 2026 (e)
298.09 M USD
96.52 M USD
77.29 M USD
Jan 1, 2027 (e)
349.18 M USD
146.23 M USD
81.60 M USD
Jan 1, 2028 (e)
254.96 M USD
55.14 M USD
35.03 M USD
Jan 1, 2029 (e)
411.19 M USD
155.40 M USD
121.95 M USD
Jan 1, 2030 (e)
503.96 M USD
221.25 M USD
173.63 M USD

Zymeworks Margins

Zymeworks stock margins

The Zymeworks margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zymeworks. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zymeworks.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
-88.11 %
-181.62 %
-156.13 %
Jan 1, 2024
100.00 %
-179.69 %
-160.80 %
Jan 1, 2025
100.00 %
-87.33 %
-76.56 %
Jan 1, 2026 (e)
100.00 %
32.38 %
25.93 %
Jan 1, 2027 (e)
100.00 %
41.88 %
23.37 %
Jan 1, 2028 (e)
100.00 %
21.63 %
13.74 %
Jan 1, 2029 (e)
100.00 %
37.79 %
29.66 %
Jan 1, 2030 (e)
100.00 %
43.90 %
34.45 %

Zymeworks Stock analysis

What does Zymeworks do? Zymeworks, Inc. generates revenue through its clinical-stage biopharmaceutical products and platforms. The company develops biotherapeutics using its Azymetric bispecific platform, which creates antibodies binding multiple targets, and its ZymeLink ADC platform, combining cytotoxins with tumor-targeting antibodies. Lead product ZW25 targets HER2 for cancer treatment, while ZW49 integrates ZW25 design with ZymeLink for enhanced therapy. These products are developed for clinical trials and potential commercialization, with revenue expected from future partnerships or sales once approved. Zymeworks focuses on oncology and immune modulation, leveraging its EFECT platform for immune cell recruitment control. The company’s platforms and product candidates are designed for pharmaceutical partnerships, with potential buyers including biopharmaceutical firms seeking innovative cancer therapies. Revenue streams will emerge from licensing agreements, milestone payments, and future product sales once clinical development progresses. The company’s product pipeline includes ZW25 and ZW49, both targeting HER2-related cancers. ZW25 uses Azymetric technology, while ZW49 incorporates ZymeLink for antibody-drug conjugates. These are developed for potential commercialization, with revenue anticipated from biopharmaceutical partners who license these technologies or products for further development and marketing. Zymeworks is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Zymeworks's Sales Figures

The sales figures of Zymeworks originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Zymeworks’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Zymeworks's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Zymeworks’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Zymeworks stock

The revenue of Zymeworks is 105.97 M USD in 2025.

The revenue of Zymeworks changed from 76.30 M USD to 105.97 M USD, representing a 38.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Zymeworks since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Zymeworks historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Zymeworks

All Key Metrics — Zymeworks